Praxis precision medicines provides corporate update and reports fourth quarter and full-year 2023 financial results

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide phase 3 studies in the essential3 program for essential tremor (et); enrollment on track to be completed in 1h 2024 with topline results in 2h 2024
PRAX Ratings Summary
PRAX Quant Ranking